Clin Drug Invest. 2005;26(4):175-183.

However, the market for all inhalation-related diseases, specifically idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), plus COPD and asthma, amounted to $28.1 billion in 2015 and is ...

Several single-dose studies comparing acute bronchodilation induced by ipratropium bromide with salbutamol have shown that salbutamol was more effective than ipratropium in asthma treatment.